• History

    The Global Fund to Fight AIDS, Tuberculosis and Malaria was created in 2002 to save lives and direct the world’s money to those most in need.

    It was the dream of Kofi Annan, former Secretary-General of the United Nations, to establish a “war chest” of funds to fight three of the deadliest infectious diseases the world has ever known. In 2000, these three diseases together accounted for 6 million deaths, often affecting people in the most productive years of their lives.

    The idea for the Global Fund arose from a wellspring of grass-roots political advocacy coming face-to-face with the imperatives of global leadership. AIDS, TB and malaria are all preventable and treatable – but solving this problem requires the commitment not only of world leaders and decision-makers but also of those working on the ground to help the men, women and children living with these diseases.

    The idea was discussed at a G8 summit in Okinawa, Japan, in 2000. The real commitment began to coalesce at the African Union summit in April 2001, continued at the United Nations General Assembly Special Session in June of that year, and was finally endorsed by the G8 at their summit in Genoa in July 2001. A Transitional Working Group was established to determine the principles and working modalities of the new organization, and the Global Fund came into being in January 2002.

    A brief timeline of important events in Global Fund history is below:

    2002

    January 2002
    The Global Fund to Fight AIDS, Tuberculosis and Malaria constituted. Secretariat established in Geneva, Switzerland.

    February 2002
    Call for Proposals launched, and named Round 1.

    April 2002
    Approval of Round 1 for a total amount of US$600 million for 36 countries. Dr Richard Feachem selected as Executive Director.

    July 2002
    Call for Proposals is launched, as Round 2.

    December 2002
    The Global Fund makes its first disbursement of US$1 million.

    2003

    January 2003
    Board approves Round 2 – US$900 million in grants to 72 countries.

    August 2003
    Total disbursements to countries surpasses US$100 million.

    December 2003
    Disbursements at the end of 2003 total US$232 million.

    2004

    June 2004
    Board approves Round 4 grants totaling US$968 million for 69 grants in 50 countries.

    2005

    December 2005
    US$1.9 billion has been disbursed.

    2006

    April 2006
    Dr. Feachem’s term is completed. The Board selects Prof Michel Kazatchkine as Executive Director.

    December 2006
    Results include:

    • 770,000 people on antiretrovirals
    • 2 million people treated for TB
    • 18 million insecticide-treated nets delivered

    2007

    September 2007
    The Global Fund’s Second Replenishment concludes with a total amount of US$9.7 billion pledged for the period 2008-2010.

    November 2007
    Board approves 73 grants in Round 7 of funding for a total of US$1.1 billion, bringing total number of countries supported to 136.

    December 2007
    Results include:

    • 1.4 million people on antiretrovirals
    • 3.3 million people treated for TB
    • 46 million insecticide-treated nets distributed

    2008

    November 2008
    Board approves 94 Round 8 grants for a total value of US$ 2.75 billion – the highest amount ever approved.

    2009

    November 2009
    Board approves Round 9 grants for a total value of US$2.4 billion.

    December 2009
    Results include:

    • 2.5 million people on antiretrovirals
    • 6 million people treated for TB
    • 104 million insecticide-treated nets distributed
    • Amount contributed by donors stands at US$3.2 billion for 2009

    2010

    October 2010
    At a meeting at the United Nations in New York, donors pledge US$9.2 billion in support for the period 2011-2013.

    2011

    January 2011
    News reports cite misused funds by sub-recipients of grants by the Global Fund in four countries.

    March 2011
    A High-Level Panel is convened to examine the Global Fund’s financial oversight and risk management.

    September 2011
    The High-Level Panel issues a report calling for structural changes in the Global Fund’s business model and specific improvements in management practices and financial oversight.

    October 2011
    The World Health Organization announces that the tuberculosis death rate has dropped by 35 percent since 1990.

    November 2011
    Board decides to suspend Round 11 due to shortage of available funding, to evolve the funding model to make it more strategic, more predictable and more responsive.

    December 2011
    Results include:

    • 3.3 million people on antiretrovirals
    • 8.6 million people treated for TB
    • 230 million insecticide-treated nets distributed

    2012

    February 2012
    Gabriel Jaramillo, a former banker and turn-around expert, begins a one-year term as General Manager to oversee a comprehensive transformation. Prof Michel Kazatchkine resigns as Executive Director.

    March 2012
    Transformation realigns workforce with a sharp increase in staff working on core business of grant management, and a special focus on high-impact countries, along with a corresponding decrease in staff in support functions.

    November 2012
    Board selects Mark Dybul as the Global Fund’s third Executive Director.

    December 2012
    Results include:

    • 4.2 million people on antiretrovirals
    • 9.2 million people treated for TB
    • 310 million insecticide-treated nets distributed

    2013

    February 2013
    Global Fund invites six countries to participate fully in the transition phase of its new funding model.

    April 2013
    At a meeting in Brussels, Belgium, the Global Fund launches its Fourth Replenishment, seeking financing for the period 2014-2016. The pledging conference will be held in December 2013.

    June 2013
    The Board awards grants to the first three countries to receive funding under the new funding model.

    December 2013
    The Global Fund’s Fourth Replenishment launches with a total amount of US$12 billion pledged for the period 2014-2016.

    Results include:

    • 6.1 million people on antiretrovirals
    • 11.2 million people treated for TB
    • 360 million insecticide-treated nets distributed